NCT03840278View on ClinicalTrials.gov

The Bihormonal iLet Bionic Pancreas Feasibility Study

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

July 3, 2019

Study Completion Date

July 3, 2019

Conditions
Type 1 Diabetes Mellitus
Interventions
DEVICE

Bihormonal iLet Bionic Pancreas

Bihormonal iLet Bionic Pancreas using insulin and dasiglucagon

DEVICE

Insulin-only Bionic Pancreas

Insulin-only iLet Bionic Pancreas using just insulin

DRUG

Dasiglucagon

Experimental stable glucagon for use in the iLet Bionic Pancreas

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Beta Bionics, Inc.

INDUSTRY

collaborator

Zealand Pharma

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT03840278 - The Bihormonal iLet Bionic Pancreas Feasibility Study | Biotech Hunter | Biotech Hunter